Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• Dopamine is considered to be an important neurotransmitter of the central nervous system. Dopamine mediates its action by binding to five different dopamine receptors. These can be classified into classes D1-Iike (D1 and D5) as well as D2-Iike (D2, D3 and D4 receptors) due to their morphology and their mode of signal transduction (Neve, KA The Dopamine Receptors, Humana Press, 1997 ). Especially the subtypes of the D2 family play an important role in the regulation of central nervous processes; While the D2 receptors are predominantly expressed in the basal ganglia, where they are involved in the control and modulation of neuromotor circuits, D3 receptors are mainly in the mesolimbic system, in which emotional and cognitive processes are controlled.
• the D3 receptor is a promising target for the development of drugs for the treatment of psychiatric disorders such as schizophrenia or unipolar depression, disorders of consciousness as well as for the treatment of neurodegenerative diseases such as Parkinsonism and occurring during long-term dyskinesia, but also to Treatment of drug dependence (Pulvirenti, L. et al Trends Pharmacol Sci 2002, 23, 151-153, Joyce, JN Pharmacol.Tur., 2001, 90, 231-259.) It is desirable to have as D3 receptor as possible. selective binding profile for such active substances. Depending on the intrinsic activity (full agonist, partial agonist, antagonist or inverse agonist), such ligands can have stimulatory, modulating or inhibitory effects on the pathologically altered dopamine signal transduction system and thus be used to treat these diseases.
• Dopamine receptors are known (Perrone, RJ Med. Chem. 1998, 41, 4903-4909, EP 0 779 284 A1). Recently, heteroarenamides have also been described as D3 receptor-active compounds (Bettinetti, L. et al., J. Med. Chem., 2002, 45, 4594-4597, Leopoldo, M., et al., J. Med. Chem , 45, 5727-5735, WO 2004004729 A1). Recently, a phenylpiperazinylnaphthamide was also used as a selective D3 Partial agonists report that shows hopeful activities in the animal model, which could be used for the treatment of cocaine addiction (PiIIa, M.
• the common structural feature of many high-affinity dopamine receptor ligands consists of a variably substituted phenylpiperazine partial structure, which is linked to an aryl or heteroaryl carboxamide via a spacer of several carbon atoms.
• Such compounds are described, for example, in Bettinetti, L. et al. J. Med. Chem. 2002, 45, 4594-4597, Campiani, G. et al. J. Med. Chem. 2003, 46, 3822-3839 and Hackling, A. et al. J. Med. Chem. 2003, 46, 3883-3889.
• the dopamine D3 receptor also recognizes ⁇ Heteroarencarboxamide as high-affinity ligand containing a nitrogen atom having basic properties in the six-membered aromatic ring system.
• the invention thus relates to azaindoles having a basic nitrogen in the six-membered ring of the heterocycle which are substituted in the 2 or 3-position of the 5-membered ring with a carboxamide unit. These showed high affinity and selective binding properties at the D3 receptor in in vitro studies. In addition, some compounds also have remarkable affinity for serotonergic receptors, especially for the 5-HT1a receptor.
• the compounds of the invention could thus be valuable therapeutics for the treatment of CNS disorders, such as schizophrenia or various types of depression, for neuroprotection in neurodegenerative disorders
• ADHD hyperactivity disorder
• hyperprolactinemia hyperprolactinoma
• autism idiopathic or drug-induced extrapyramidal motor movement disorders, e.g. Akathisia, rigor, dystonia and dyskinesia as well as various diseases of the urinary tract represent.
• the invention relates to compounds of general formula I,
• A is an aromatic 6-membered ring whose ring-forming C atoms can each independently carry a substituent R 1;
• B is an aromatic 5-membered ring bearing exactly one group X;
• Q1 is N, N-R '; S, O, CH, C-R1 or C-X;
• Q2 is CH, C-R1 or C-X, where either Q1 or Q2 form a group C-X;
• R1 is independently selected from hydroxy, alkyl, alkyloxy, alkylthio, alkenyl, alkynyl, phenyl, phenylalkyl, phenoxy, halogen, trifluoromethyl, alkylcarbonyl, phenylcarbonyl, phenylalkylcarbonyl, alkyloxycarbonyl, phenylalkyloxycarbonyl, cyano, nitro, amino, carboxy, sulfo, sulfamoyl, Sulfonylamino, alkylaminosulfonyl and alkylsulfonylamino
• R ' is selected from hydrogen, alkyl, phenyl, phenylalkyl, alkylcarbonyl, phenylcarbonyl, phenylalkylcarbonyl and phenylsulfonyl;
• R is absent when Q1 represents N-R ', S or O or R is selected from hydrogen, alkyl, phenyl, phenylalkyl, alkylcarbonyl, phenylcarbonyl, phenylalkylcarbonyl and phenylsulfonyl when Q1 is N, CH, C-R1 or C-X.
• X is a group with the general formula X1
• Y is an unbranched, saturated or unsaturated hydrocarbon chain of 2-5 carbon atoms or a chain - (CH 2) O -Z- (CH 2) P , wherein Z is selected from the radicals cyclopentyl, cyclohexyl and cycloheptyl, where o and p are each independently have the value 0, 1, 2 q of 3 and where the sum of o and p is at most 3;
• R 2, R 3, R 4, R 5 and R 6 are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkyloxy, alkylthio, alkenyl, alkynyl, phenyl, phenylalkyl, phenoxy, halogen, trifluoromethyl, alkylcarbonyl, phenylcarbonyl, phenylalkylcarbonyl, alkyloxycarbonyl, phenylalkyloxycarbonyl , Cyano, nitro, amino, carboxy, sulfo, sulfamoyl, sulfonylamino, alkylaminosulfonyl and alkylsulfonylamino, wherein two adjacent radicals R 2, R 3, R 4, R 5 and R 6 together with the C atoms of the phenyl ring to which they are attached, an oxygen-containing Can form -, 6- or 7-membered ring; R 7 is alkyl or, preferably,
• the substituents R 1 of the heteroarene in the compounds of general formula I according to the invention are selected from the group hydroxy; Fluorine; Chlorine; Bromine; trifluoromethyl; cyano; amino; carboxy; sulfo; sulfamoyl; unsubstituted or hydroxy-substituted C1-C6 alkyl; unsubstituted or hydroxy-substituted C1-C6 alkyloxy; unsubstituted or hydroxy-substituted C1-C6 alkylthio; unsubstituted C 2 -C 6 alkynyl; unsubstituted or substituted by fluorine, chlorine or bromine and / or one or more methoxy phenyl; Phenyl (C 1 -C 6) alkyl, wherein the phenyl is unsubstituted or substituted by fluorine, chlorine or bromine and / or by one
• R 2, R 3, R 4, R 5 and R 6 are preferred in the compounds of general formula I according to the invention and are each independently selected from the group consisting of hydrogen, hydroxy; Fluorine; Chlorine; Bromine; trifluoromethyl; cyano; amino; carboxy; sulfo; sulfamoyl; unsubstituted or hydroxy-substituted C1-C6 alkyl; unsubstituted or hydroxy-substituted C1-C6 alkyloxy; unsubstituted or hydroxy-substituted C1-C6 alkylthio; unsubstituted C 2 -C 6 alkynyl; unsubstituted or substituted by fluorine, chlorine or bromine and / or one or more methoxy phenyl; Phenyl (C 1 -C 6) alkyl, wherein the phenyl is unsubstituted or substituted by fluorine, chlorine or bromine and / or by
• Y in the compounds according to the invention is a chain - (CH 2 ) pZ- (CH 2 ) o-, wherein Z is selected from the radicals cyclopentyl, cyclohexyl and cycloheptyl, and wherein p and o are independently selected from 0.1 and 2 and together give a value of at most 2 or 1 or both are 0.
• X thus particularly preferably represents a group of the general formula X 2 Formula X2
• n has the value 2-5 and particularly preferably the value 4 or 5 and the substituents R 2, R 3, R 4, R 5, R 6 and R 7 have the meaning as described above.
• At least one of the two radicals R 2 and R 3 is a substituent other than hydrogen, in particular halogen, C 1 -C 6 -alkyl or C 1 -C 6 -alkyloxy, while the radicals R 4, R 5 and R 6 in the compounds of general formula I according to the invention or in formula X1 and formula X2 are each hydrogen.
• one of the two substituents R 2 or R 3 is a halogen, in particular fluorine or chlorine, particularly preferably R 2 and R 3 are both halogen, very particularly preferably chlorine.
• A is a 6-membered aromatic ring whose ring-forming C atoms independently of one another can each carry a substituent R 1;
• B is an aromatic 5-membered ring bearing exactly one group X; , •
• Q1 is N, N-R '; CH, C-R1 or C-X;
• Q2 is CH, C-R1 or C-X, where either Q1 or Q2 form a group C-X;
• Q3 is N, CH or C-R1
• R1 in the compounds of the general formula Ia is in each case independently selected from the group hydroxy; Fluorine; Chlorine; Bromine; trifluoromethyl; cyano; amino; carboxy; sulfo; sulfamoyl; unsubstituted or hydroxy-substituted C1-C6 alkyl; unsubstituted or hydroxy-substituted C1-C6 alkyloxy; unsubstituted or hydroxy-substituted C1-C6 alkylthio; unsubstituted C 2 -C 6 alkynyl; unsubstituted or substituted by fluorine, chlorine or bromine and / or one or more methoxy phenyl; Phenyl (C 1 -C 6) alkyl, wherein the phenyl is unsubstituted or substituted by fluorine, chlorine or bromine and / or by one or more methoxy groups and wherein the C 1 -C 6
• R ' is selected from hydrogen; unsubstituted or hydroxy-substituted C1-C6 alkyl; unsubstituted or substituted by fluorine, chlorine or bromine and / or one or more methoxy phenyl; Phenyl (C 1 -C 6) alkyl, wherein the phenyl unsubstituted or substituted by fluorine, chlorine or bromine and / or by one or more methoxy groups and wherein the C1-C6 alkyl is unsubstituted or substituted by hydroxy; -C (O) - (C 1 -C 6) alkyl wherein the alkyl is unsubstituted or substituted with hydroxy; -C (O) -phenyl, wherein the phenyl is unsubstituted or substituted by fluorine, chlorine or bromine and / or by one or more methoxy groups; -C (O) - (I-C6) alkyl-phenyl
• R is selected from the group of hydrogen; unsubstituted or hydroxy-substituted C1-C6 alkyl; unsubstituted or substituted by fluorine, chlorine or bromine and / or one or more methoxy phenyl; Phenyl (C 1 -C 6) alkyl wherein the phenyl is unsubstituted or substituted by fluoro, chloro or bromo and / or by one or more methoxy groups and wherein the C 1 -C 6 alkyl is unsubstituted or substituted by hydroxy; -C (O) - (C 1 -C 6) alkyl wherein the alkyl is unsubstituted or substituted with hydroxy; -C (O) -phenyl, wherein the phenyl is unsubstituted or substituted by fluorine, chlorine or bromine and / or by one or more methoxy groups;
• X in compounds of general formula Ia is a group of general formula X2
• n is 2-5 and more preferably 4 or 5 and in which the substituents R 2, R 3, R 4, R 5, R 6 and R 7 are preferred and each independently are selected from the group group hydrogen, hydroxy; Fluorine; Chlorine; Bromine; trifluoromethyl; cyano; amino; carboxy; sulfo; sulfamoyl; unsubstituted or hydroxy-substituted C1-C6 alkyl; unsubstituted or hydroxy-substituted C1-C6 alkyloxy; unsubstituted or hydroxy-substituted C1-C6 alkylthio; unsubstituted C 2 -C 6 alkynyl; unsubstituted or substituted by fluorine, chlorine or bromine and / or one or more methoxy phenyl; Phenyl (C 1 -C 6) alkyl, wherein the phenyl is unsubstituted or substituted by fluorine, chlorine
• R 7 is C 1-6 alkyl or, preferably, hydrogen
• Exemplary compounds of the formula I or Ia are selected from Formula purple Formula IHb Formula IV
• R, R 'and X each have the meaning as described further above under the formulas I and Ia and
• the C atoms of the ring A can each independently bear a substituent R 1, as further defined above under the formulas I and Ia.
• the invention relates to compounds of the general formula II
• the substituent X is linked to position 2 or 3 of the pyrrolo [2,3-b] pyridine and represents a group as described further above under formula I or formula Ia;
• the pyrrolo [2,3-b] pyridine can carry substituents R1 in positions 4-6 of the A-ring or at the non-X linked position 2 or 3 of the B-ring, as described further below under formula I or formula Ia wherein the pyrrolo [2,3-b] pyridine 'is preferably at most two substituents R1 and more preferably unsubstituted;
• R is a group as described further above under formula I or formula Ia and is preferably a hydrogen atom, a methyl group or a phenylsulfonyl;
• the substituent X is preferably formed in the compounds of general formula II as a group of general formula X2 Formula X2
• n 2, 3, 4 or 5 and more preferably 4 or 5;
• R 2, R 3, R 4, R 5, R 6 and R 7 are substituents as described further above under formula I or formula Ia; in preferred embodiments, R4, R5 and R6 are each hydrogen, while R2 and R3 are selected, for example, from hydrogen, chlorine, fluorine, methoxy, ethoxy, propoxy, methyl, ethyl and propyl; In another preferred embodiment, the invention relates to compounds of the general formula II wherein at least one of the substituents R 2 or R 3 is selected from chlorine, fluoro methoxy, ethoxy, propoxy, methyl, ethyl and propyl.
• the invention relates to compounds of general formula IIIa or IIIb
• the imidazo [4,5-b] pyridine can bear one or more substituents R 1 in the A ring, as described further above under formula I or formula Ia, where the A ring preferably bears at most two substituents R 1 and unsubstituted in a preferred embodiment is;
• R and R ' are groups as further described above under formula I or formula Ia.
• a preferred embodiment of the invention relates to compounds of the formula IUb, in particular when the substituent R is a hydrogen atom or a phenylsulfonyl.
• the substituent X in the compounds of the general formula III in particular in the compounds of the formula IIIb, is formed as a group of the general formula X.sup.2 Formula X2
• n 2, 3, 4 or 5 and more preferably 4 or 5;
• R 2, R 3, R 4, R 5, R 6 and R 7 are substituents as described further above under formula I or formula Ia; in preferred embodiments, R4, R5 and R6 are each hydrogen, while R2 and R3 are selected, for example, from chlorine, fluorine, methoxy, ethoxy, propoxy, methyl, ethyl and propyl; In another preferred embodiment, the invention relates to compounds of the general formula III, wherein at least one of the substituents R 2 or R 3 is a methoxy group or a halogen atom. In another embodiment, the substituent R4 is a substituent other than hydrogen, e.g. Fluorine.
• the invention relates to compounds of general formula IV
• Substiuent X is linked in positions 5 or 6 with the heteroarene nucleus and represents a group as described further above under formula I or formula Ia;
• the pyrrolo [2,3-d] pyrimidine may carry substituents R1 in positions 2 and 4 of the A-ring or at the non-X linked position 5 or 6 of the B-ring, as described further below under formula I or formula Ia described; in exemplary
• a compound of formula IV carries one or two substituents R1 selected from hydroxy and C1-C3 alkyl; in another embodiment, the pyrrolo [2,3-d] pyrimidine bears no substituent R1; ,
• R in compounds of the formula IV is a group as described further above under formula I or formula Ia and preferably represents hydrogen, phenylsulfonyl or phenyl which is unsubstituted or substituted by one or more halogen atoms.
• the substituent X in the compounds of the general formula IV in particular in the compounds of the formula HIb, is formed as a group of the general formula X.
• n 2, 3, 4 or 5 and more preferably 4 or 5; ' ⁇
• R 2, R 3, R 4, R 5, R 6 and R 7 are substituents as described further above under formula I or formula Ia; in preferred embodiments, R4, R5 and R6 are each hydrogen, while at least one of the substituents R2 and R3 is exemplified by chlorine, fluorine, methoxy, ethoxy, propoxy, methyl, ethyl and propyl; in a preferred embodiment, the invention relates to compounds of the general formula IV, wherein at least one of the substituents R 2 or R 3 is a methoxy group or a halogen atom. ' . ⁇
• the invention also relates to physiologically acceptable salts of the compounds of the invention. Examples of such salts are described in the definitions below.
• Alkyl can be a branched or unbranched alkyl group which preferably has 1 to 10 C atoms, particularly preferably 1 to 6 C atoms ("C 1 -C 6 alkyl”) and very particularly preferably 1, 2 or 3 C atoms.
• C1-C6 alkyl includes, for example Methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, s-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, t-pentyl, 1-methylbutyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl and n-hexyl.
• Alkyl may also be cyclic or contain a cyclic portion, with cycles of 3-7 carbon atoms being preferred, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. "Alkyl” is preferably not cyclic and contains no cyclic portion. Alkyl groups may additionally be substituted with one or more substituents, in particular with hydroxy or amine. Preferably, "alkyl” is unsubstituted or substituted with hydroxy.
• Alkenyl and alkynyl have at least one double or triple bond. They may be branched or unbranched and preferably have 2 to 6 carbon atoms. Alkenyls or alkynyls are preferably attached to the heteroarene or phenyl ring of the backbone of the compound such that the double or triple bond is conjugated to the aromatic ring. Alkenyl and alkynyl may additionally be substituted with one or more substituents, preferably with phenyl, the phenyl group then being particularly preferably at the C atom 2 (when alkenyl or ⁇ alkynyl via the C atom 1 to the heteroarene or phenyiring of the backbone is bound). Preferably, the alkenyls or alkynyls are unsubstituted.
• Alkyloxy is the group -O-alkyl, wherein alkyl is preferably selected from the groups identified above for “alkyl”.
• Alkyloxy means a C1-C6 alkyloxy group is preferable, particularly preferably methoxy ⁇ .. -
• Alkylthio is the group -S-alkyl wherein alkyl is preferably selected from the groups identified above for “alkyl.”
• alkylthio is a C1-C6 alkyl-S group.
• Alkylaminosulfonyl includes the groups -SO 2 -NH-alkyl and -SO 2 -N-dialkyl wherein alkyl is preferably selected from the groups identified above for "alkyl.”
• alkyl in “alkylaminosulfonyl” is a C 1 -C 6 alkyl group.
• alkylaminosulfonyl include methylaminosulfonyl, N. N-dimethylaminosulfonyl or butylaminosulfonyl.
• Alkylsulfonylamino is the group -NH-SO 2 -alkyl, wherein alkyl is preferably selected from the groups identified above for “alkyl.”
• alkylsulfonylamino is a C 1 -C 6 -alkylsulfonylamino group, eg, methanesulfonylamino.
• Phenyl is preferably unsubstituted, but may optionally be substituted one or more times independently, for example with alkoxy, alkyl, trifluoromethyl or halogen.
• Phenylalkyl is the group -alkyl-phenyl wherein phenyl and alkyl are as defined above, for example, phenylalkyl includes phenylethyl and benzyl and is preferably benzyl.
• Phenoxy is the group -O-phenyl, wherein phenyl has the meaning as further defined above.
• Alkylcarbonyl includes the group -C (O) -alkyl wherein alkyl is preferably selected from the groups identified above for “alkyl", and more preferably -C (O) -CI-C6-alkyl. "Alkylcarbonyl” is preferably acetyl, propioyl or butyryl.
• Phenylcarbonyl is -C (O) -phenyl, wherein phenyl has the meaning as defined above
• Phenylalkylcarbonyl is -C (O) -alkyl-phenyl, wherein alkyl and phenyl have the meaning as defined above.
• Alkyloxycarbonyl is the group -C (O) -O-alkyl, wherein alkyl is preferably selected from the groups identified above for “alkyl”.
• alkyl is preferably selected from the groups identified above for "alkyl”.
• alkoxycarbonyl is a (C 1 -C 6 -alkyl) oxycarbonyl group.
• Phenylalkyloxycarbonyl is the group -C (O) -O-alkyl-phenyl, wherein alkyl and phenyl have the meaning as defined above.
• Halogen includes fluoro, chloro, bromo and iodo, and is preferably fluoro, chloro or bromo.
• “Sulfamoyl” includes the group -SO 2 -NH 2 .
• “Sulfonylamino” includes the group -NH-SO 2 H.
• “Physiologically acceptable salts” include non-toxic addition salts of a base, especially a compound of formulas (I) to (IV) in the form of the free base, with organic or inorganic acids.
• organic or inorganic acids include HCl, HBr, sulfuric acid and phosphoric acid.
• Organic acids include acetic, propionic, pyruvic, butyric, ⁇ -, ⁇ - or ⁇ -hydroxybutyric, valeric, hydroxyvaleric, caproic, hydroxycaproic, caprylic, capric, lauric, myristic, palmitic, stearic, glycolic, lactic, D-glucuronic, L, acids Glucuronic acid, D-galacturonic acid, glycine, benzoic acid, hydroxybenzoic acid, gallic acid, salicylic acid, vanillic acid, coumaric acid, caffeic acid, hippuric acid, orotic acid, L-tartaric acid, D-tartaric acid, D, L-tartaric acid, meso-tartaric acid, fumaric acid, L-malic acid ' e, D-malic, D, L-malic, oxalic, malonic, succinic, maleic, oxalacetic, glutaric, hydroxyglutaric, ketoglu
• Compounds of formulas (I) to (IV) as defined are suitable as pharmaceuticals.
• the compounds of the invention include affinity or even high affinity ligands for D3 receptors.
• D3-affine ligand includes compounds that bind to human dopamine in a radioligand experiment (see, Hübner, H. et al., J. Med. Chem., 2000, 43, 756-762 and the "Biological activity” section) D3 receptors with a Show Ki value of not more than 500 nM For "affine" ligands of other receptors, the definition applies accordingly.
• high-affinity D3 ligands includes compounds that bind to human dopamine D3 in a radioligand experiment (see, Hübner, H. et al., J. Med. Chem., 2000, 43, 756-762 and the "Biological activity” section) Receptors having a Ki value of preferably not more than about 30 nM, more preferably not more than 3 nM show. For "high affinity" ligands of other receptors the definition applies accordingly.. • • • •
• selective D3 ligands includes compounds which have a Ki value lower by at least a factor of at least 10 in the radioligand experiment for the D3 receptor, as described in the "Biological Activity” section below, for at least five of the seven following receptors is: dopamine D1, D2long, D2short and D4.4, serotonin receptors 5-HT1A and 5-HT2 and alpha 1 adrenoceptor.
• Another aspect of the invention relates to highly selective dopamine D3 ligands.
• the term "highly selective D3 ligand” encompasses compounds that, • a Ki value have in Radioligandexperiment as described below in "Biological activity" for the D3 receptor, which by a factor of at least 100 lower than, for at least three preferred for all of the dopamine receptors D1, D2long, D2short and D4.4.
• D3 ligands may have agonist, antagonist or partial agonist activity at the D3 receptor.
• the corresponding intrinsic activities of the compounds according to the invention can be measured in mitogenesis assays as described in the literature (Hübner, H. et al., J. Med. Chem., 2000, 43, 4563-4569 and Löber, S. Bioorg., Med. Lett. 2002, 12.17, 2377-2380).
• mitogenesis assays as described in the literature (Hübner, H. et al., J. Med. Chem., 2000, 43, 4563-4569 and Löber, S. Bioorg., Med. Lett. 2002, 12.17, 2377-2380).
• a more agonistic, more antagonistic or a partial agonist activity may be desired therapeutically.
• some of the substances according to the invention also have significant affinity for other pharmacologically interesting receptors, such as the serotonin receptor, in particular the 5-HT1a receptor, or the dopamine D2 receptor.
• the serotonin receptor in particular the 5-HT1a receptor
• the dopamine D2 receptor instead of a highly selective dopamine D3 receptor binding, depending on the type of the disease to be treated, binding to a further receptor may also be desired.
• a compound that is a high affinity D3 ligand and, at the same time, an affine or even high affinity 5-HT1a receptor ligand may be attractive.
• the addition D3-modulatory properties and D2 agonist, alpha! ". urinary incontinence may even be desirable for greater selectivity to the serotonin receptor.
• the present invention therefore excellently permits a fine adjustment of the desired affinity, activity and selectivity with respect to various pharmacologically important receptors, in particular the dopamine D3 receptors, but also, for example, with respect to the 5-HT1a receptor or the D2 receptor.
• Another object of the invention is therefore a pharmaceutical composition which contains one or more of the compounds of the general formulas (I) to (IV) or one of the compounds specifically listed above as defined, optionally in the form of a pharmaceutically acceptable salt and a pharmaceutically acceptable auxiliary.
• the invention also relates to the use of one or more of the compounds of general formulas (I) to (IV) or one of the compounds specifically listed, optionally in the form of a pharmaceutically acceptable salt, for the treatment, the indications mentioned here and for the manufacture of a medicament for the here mentioned indications.
• treatment of a disease in this patent application includes the treatment of an already existing disease as well as (b) the prophylaxis of a not yet or not yet fully developed disease, if there is a risk for the occurrence of such a disease.
• preference is given to selecting compounds of the invention which are high-affinity D3 ligands. Particular preference is given to using selective or even highly selective D3 ligands.
• compounds are selected which are affine or even highly affine, or in particular for the 5-HT1a receptor.
• the compounds according to the invention have potential in the therapy or prophylaxis of a number of diseases which are associated, in particular, with a disorder of the dopamine metabolism or the dopaminergic signal cascade or, if appropriate, the serotonergic signal transmission.
• An object of the invention is therefore the use of a compound according to the invention, as described in this patent application including the claims and the examples, for the preparation of a medicament for the treatment of diseases that are associated with a disorder of Dopaminstoff Touch Touchs and / or the dopaminergic signal cascade.
• Another object of the invention is the use of a compound of the invention, as described in this patent application including the claims and the examples, for. Preparation of a medicament for the treatment of diseases associated with a disorder of serotonin metabolism and / or serotonergic signaling.
• CNS disorders encompasses both disorders which originate in the CNS and whose symptoms are predominantly or exclusively noticeable in the CNS, such as, for example, psychosis, depression or cognitive disorders, as well as diseases which originate in the CNS whose symptoms are at least partly noticeable in other target organs, such as extrapyramidal motor movement disorders or hyperprolactinemia.
• CNS disorders that can be treated with the compounds of the invention are
• psychosis and anxiety disorders including mania, idiopathic psychosis,
• Schizophrenia obsessive-compulsive disorder, panic attacks, phobias, eating disorders, aggressive and autoagressive disorders, stereotypes and other personality disorders
• mood disorders e.g. depressive disorders, in particular major depression, manic-depressive disorders, organic-induced depression, for example in connection with neurodegenerative diseases such as Parkinson's disease or Alzheimer's
• Movement disorders including tremor, rigors, dyskinesia, dystonia, as in Parkinson's disease, Parkinsonism (idiopathic, eg, Parkinson-Plus syndrome or drug-induced, eg, after L-dopa, or neuroleptic treatment), Segawa syndrome, Tourette's disease. Syndrome, restless leg syndrome
• Dopamine antagonists may be used either alone or in combination with 5-HT3 antagonists
• neurodegenerative diseases may be mentioned because, due to their neuroprotective effect, the substances may delay or arrest the destruction or loss of neurons as a cause or consequence of a pathophysiological event.
• diseases are, for example, the otomyotropic lateral sclerosis, the Alzheimer's disease, Huntington's chorea, epilepsy, Parkinson's disease, or synucleopathies, for example of the Parkinson-Plus syndrome type.
• substances of the invention can also be used to other diseases ⁇ treatment, inconclusive or CNS associated are not exclusive.
• disorders are especially disorders of the urinary tract, such as sexual dysfunction, especially male erectile dysfunction and urinary incontinence.
• urinary incontinence in particular compounds with a pronounced serotonergic active component are suitable.
• An object of the invention is therefore the use of a compound of the invention for the manufacture of a medicament for the treatment of diseases of the urinary tract, in particular of male erectile dysfunction and urinal incontinence.
• Diseases for which the compounds of the present invention are particularly useful are schizophrenia, depressive disorders, L-dopa or neuroleptics-induced movement disorders, Parkinson's disease, Segawa syndrome, restless leg syndrome, hyperprolactinemia, hyperprolactinoma, hyperactivity disorder (ADHD) and urinary incontinence.
• Parkinson's disease-associated movement disorders e.g. Rigor, tremor, dystonia and dyskinesia, Segawa syndrome
• the medicaments according to the invention may also be in the form of a combined preparation for simultaneous or sequential administration.
• a sales unit containing an L-Dopa medication containing Parkinson's disease may also comprise a pharmaceutical composition containing one or more of the compounds of the invention having, for example, a highly selective, partial agonist dopaminergic and / or serotonergic profile of action.
• L-dopa and the compound according to the invention may be present in the same pharmaceutical formulation, eg a combination tablet, or else in different application units, for example in the form of two separate tablets. Depending on your needs, both active ingredients can be used simultaneously. or administered separately.
• sequential administration can be achieved by using a dosage form, e.g. an oral tablet having two distinct layers with differing release profiles for the various pharmaceutically active ingredients.
• a dosage form e.g. an oral tablet having two distinct layers with differing release profiles for the various pharmaceutically active ingredients.
• One embodiment of the invention therefore relates to a medicament containing L-dopa or a neuroleptic and a compound of the invention for simultaneous or sequential administration to the patient.
• the vending unit may be a combination preparation or contain two application units containing two of the compounds according to the invention with different receptor profile, e.g. a high affinity, highly selective D3 modulator and a high affinity 5-HT1 a modulator.
• Another object of the invention is a method for treating a disease selected from the diseases listed above, by administering one or more of the compounds of the invention, each alone or in combination with other drugs to a mammal in need of such treatment, wherein the term "Mammals” also includes and in particular humans.
• the pharmaceutical compositions according to the invention consist of a pharmaceutical composition, in addition to the compounds according to the invention, as above contains at least one pharmaceutically acceptable carrier or excipient.
• the pharmaceutical formulation can be designed differently depending on the intended route of administration.
• the pharmaceutical formulation may be adapted for intravenous, intramuscular, intracutaneous, subcutaneous, oral, buccal, sublingual, nasal, transdermal, inhalative, rectal or intraperitoneal administration.
• the pharmaceutical compositions containing the compounds of the invention are administered orally and can be present for example as a capsule, tablet, powder, granulate, dragee 'or in liquid form.
• the formulation may be designed as a rapidly releasing dosage form, if a rapid onset of action is desired.
• Corresponding oral formulations are described, for example, in EP 0 548 356 or EP 1 126 821.
• a formulation with a sustained-release release is suitable .
• Corresponding oral formulations are also known from the prior art.
• Alternative pharmaceutical preparations may be, for example, infusion or injection solutions, oils, suppositories, aerosols, sprays, patches, microcapsules or microparticles.
• the compounds of the formulas (I) to (IV) are prepared by methods which are already partially described in the literature (Bettinetti, L. et al., J-Med. Chem. 2002, 45, 4594-4597).
• the acid derivatives of type (A) either synthesized according to literature, generated from commercially available precursors or their preparation methods have been elaborated in our laboratories, in the form of their carboxylic acid chlorides or alternatively by using special activating reagents such as hydroxybenzotriazole, hydroxyazabenzotriazole, HATU (Kienhöfer , A. Synlett 2001, 1811-1812) or TBTU (Knorr, R. Tetrahedron Lett. 1989, 30, 1927-1930) and with the free base of the type (C) to the derivatives ⁇ of the formula (I) and (II ) implemented.
• special activating reagents such as hydroxybenzotriazole, hydroxyazabenzotriazole, HATU (Kienhöfer , A. Synlett 2001, 1811-1812) or TBTU (Knorr, R. Tetrahedron Lett. 1989, 30, 1927-1930) and with the free base of the type (C) to the derivatives
• the compounds according to the invention are prepared by reacting an acid derivative A.
• W is selected from OH, Cl, Br or a group
• Heteroaren stands for a group that is selected from
• A, B, Q3 and R are each as defined further above in the preparation of the compounds of the invention.
• Q1 and Q2 each have the meaning as defined above but do not represent C-X;
• the crossed bond in the heteroarenes represents a bond of the group -C (O) -W to a ring-forming C atom of the 5-membered ring of the heteroarene;
• heteroarenes may be substituted one or more times by R1, as defined further above;
• Y, R2, R3, R4, R5 and R6 are each as defined further above,
• the appropriate acid group is activated prior to reaction with the free base of general formula C by ⁇ addition of activating reagents, such as hydroxybenzotriazole, hydroxyazabenzotriazole, HATU and TBTU.
• W is preferably chlorine, bromine or OH and particularly preferably chlorine or OH.
• Diaminopyridine with glycolic acid or lactic acid and subsequent oxidation by means of potassium permanganate Li. Bukowski, M. Janowiec, Z. Zwolska-Kwiek, Z. Andrejczyk Pharmacy, 1999, 54, 651-654.
• azaindolecarboxylic acids can be prepared according to the synthesis of the corresponding pyridine or pyrimidine derivatives with trialkyloxyacetic acid alkyl ester described in the literature (JH Musser, TT Hudec, K. Bailey, Synth. Comm. 1984, 14, 947-953) and subsequent saponification ,
• the synthesis of pyrrolopyrimidine-5-carboxylic acid can be carried out by saponification of the corresponding ester (B.G. Ugarkar et al., J. Med. Chem. 2000, 43, 2883-2893).
• arylpiperazinylamines of type (C1) e.g., 2-methoxy- or 2,3-dichlorophenylpiperazines are alkylated with bromobutylphthalimide in xylene. Subsequent hydrazinolysis of the phthalimide-substituted structures yields the primary amines of type (C1). This is exemplified by the following reaction scheme:
• An alternative synthetic route for obtaining differently substituted phenylpiperazinylalkylamines of the type (C2) represents the reaction of the piperazine with a cyanoalkyl halide of corresponding chain length; as exemplified in the following reaction scheme:
• trans-4- (4-azidomethylcyclohexylmethyl) -1- (2-methoxyphenyl) piperazine begins by dissolving 0.39 g (2.3 mmol) of trans-4-azidomethylcyclohex-1-ylcarbaldehyde and 0.56 g (2.9 mmol) of 2-methoxyphenylpiperazine in 15 ml of dichloromethane and the addition of 0.74 g (3.5 mmol) of sodium triacetoxyborohydride. After 23 hours of reaction at room temperature, the mixture is washed with NaHCO 3 solution, which concentrated organic phase and purified by flash chromatography (EtOAc gasoline: 1-1). ,
• trans-4- (4-aminomethylcyclohex-1-ylmethyl) -1- (2-methoxyphenyl) piperazine is prepared by the preparation of a solution of 0.40 g (1.2 mmol) of trans-4- (4-azidomethylcyclohexylmethyl) -1- (2-methoxyphenyl) piperazine in 10 ml of methanol and addition of 0.10 g of Pd / C 10%. The suspension is stirred under H 2 atmosphere for 23 hours at room temperature. The solvent is then evaporated in vacuo and purified by flash chromatography (CH 2 Cl 2 -CH 3 OH-NEtMe 2 : 90-8-2). Yield: 0.14 g (39%) (slightly yellowish oil).
• trans-4- (4-aminomethylcyclohex-1-ylmethyl) -1- (2,3-dichlorophenyl) piperazine To produce trans-4- (4-aminomethylcyclohex-1-ylmethyl) -1- (2,3-dichlorophenyl) piperazine, to a solution of 0.20 g (0.52 mmol) of trans-4- (4-azidomethylcyclohexylmethyl ) -1- (2,3-dichlorophenyl) piperazine in 25 ml of dry THF 1.05 ml of LiAlH 4 solution (1 M in THF) and heated under reflux for 8 hours. The The solution is evaporated in vacuo and purified by flash chromatography (CH 2 Cl 2 -CH 3 OH- NEtMe 2 : 90-8-2). Yield: 0.13 g (36%) (slightly yellowish oil).
• 0.036 g (0.12 mmol) of the pyrrolo [2,3-b] pyridin-2-ylcarboxylic acid are dissolved in 4 ml of dry methylene chloride and 0.06 ml (0.13 mmol) of DIPEA are added.
• 0.065 g (0.13 mmol) of the HATU dissolved in 1 ml of DMF are slowly added dropwise at 0 ° C.
• 0.036 g (0.13 mmol) of 4- (4-aminobutyl) -1- (2-methoxyphenyl) piperazine are dissolved in methylene chloride and added dropwise at 0 ° C to the reaction solution.
• Example 21 The synthesis can be carried out analogously to the preparation of Example 17.
• Example 21 The synthesis can be carried out analogously to the preparation of Example 17.
• Example 33 The synthesis can be carried out analogously to the preparation of Example 29.
• Example 33
• the binding assays were carried out by incubating the receptor homogenates with the radioligand [ 3 H] spiperone and the compound to be tested in various concentrations.
• the affinities for the D1 receptor were determined using native membrane homogenates obtained from the striatum of the pig and the D1-selective radioligand [ 3 H] SCH 23390..
• the measurement of the binding strengths of the compounds to the serotonin receptor subtypes 5-HT1A and 5-HT2 were carried out according to methods described by us (Heindl, C. et al., Tetrahedron: Asymmetry 2003, 14, 3141-3152).
• porcine cortex membrane preparations with the radioligands [ 3 H] 8-OH-DPAT (for 5-HT1A) or [ 3 H] ketanserin (5-HT2) and the compounds in various Concentrations.
• the affinity of the test compounds for the porcine ⁇ 1 receptor was investigated, using porcine cortex membrane preparations and the ⁇ 1 -selective radioligand [ 3 H] prazosin.
• Table 1 Binding data and selectivity patterns of the compounds of formula I and II for the dopamine receptors porcineDI, human D2long, human D2short, human D3 and human D4.4 a
• Example 2 1300 180 110. 9.3 130 19 12 14
• Example 3 440 19 6.5 0.13 42 150 34 320
• Example 4 680 68 39 0.80 110 85 49 140 determined for D2long, D2short, D3 and D4.4 with the radioligand [HJSpiperon and for D1 with [ 3 H] SCH 23390; b average values from 2-6 individual experiments carried out in each case as triplicates
• Example 2 14 1100 4,6 1, 5 120 0,49
• Example 4 16 200 21 20 250 26 a determined for 5-HT1 A with the radioligand [ a H] 8-OH-DPAT, for 5-HT2 with

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Hospice & Palliative Care (AREA)
• Ophthalmology & Optometry (AREA)
• Addiction (AREA)
• Vascular Medicine (AREA)
• Pain & Pain Management (AREA)
• Psychology (AREA)
• Anesthesiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Diabetes (AREA)
• Gynecology & Obstetrics (AREA)
• Reproductive Health (AREA)
• Otolaryngology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35929547

Family Applications (1)

Country Status (15)

Families Citing this family (20)

Family Cites Families (9)

• 2004
  • 2004-11-12 DE DE102004054634A patent/DE102004054634A1/de not_active Ceased
• 2005
  • 2005-11-11 MX MX2007005649A patent/MX2007005649A/es not_active Application Discontinuation
  • 2005-11-11 JP JP2007540597A patent/JP2008519797A/ja active Pending
  • 2005-11-11 KR KR1020077009695A patent/KR20070083843A/ko not_active Application Discontinuation
  • 2005-11-11 CN CNA2005800387992A patent/CN101056878A/zh active Pending
  • 2005-11-11 CA CA002575668A patent/CA2575668A1/en not_active Abandoned
  • 2005-11-11 EA EA200700909A patent/EA200700909A1/ru unknown
  • 2005-11-11 EP EP05805690A patent/EP1771448A1/de not_active Withdrawn
  • 2005-11-11 BR BRPI0517846-0A patent/BRPI0517846A/pt not_active IP Right Cessation
  • 2005-11-11 WO PCT/EP2005/012127 patent/WO2006050976A1/de active Application Filing
  • 2005-11-11 AU AU2005303904A patent/AU2005303904A1/en not_active Abandoned
  • 2005-11-11 US US11/667,601 patent/US20070299091A1/en not_active Abandoned
• 2006
  • 2006-12-25 IL IL180317A patent/IL180317A0/en unknown
• 2007
  • 2007-01-09 ZA ZA200700252A patent/ZA200700252B/xx unknown
  • 2007-05-22 NO NO20072601A patent/NO20072601L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events